The Hematologist

banner image

ASH in Cuba

Following ASH's executive committee's retreat in Cuba, Dr. Gotlib discusses lessons, challenges and opportunities for hematologists and the community.

Read more
banner image

When is Negative Phase III Trial Positive in Sickle Cell Anemia?

Dr. DeBaun covers a study for an antiplatelet agent to reduce severity and frequency of acute vaso-occlusive pain in SCD patients.

Read more
banner image

Pros & Cons of Dexamethasone vs. Prednisone in Childhood ALL

Dr. Raetz compares two drugs for the induction phase of treatment of childhood ALL.

Read more
Current Issue Static Feature

Current Issue

July/August 2016              
Volume 13, Issue 4

Read current issue

President's Column

Dr Charles Abrams - new designProfessor of Medicine, Pathology, and Laboratory Medicine; Director PENN-CHOP Blood Center for Patient Care and Discovery, Philadelphia, PA
Open Borders Open MindsJune 23, 2016

Dr. Charles Abrams talks about the ASH executive committee's experience in Havana, Cuba during this year's retreat.

View all president's column articles

  • Medicare’s Inpatient Proposed Rule and What it Means for Hematology
    April 21, 2016

    The Centers for Medicare and Medicaid Services (CMS) released the annual set of proposals governing payments for services provided to patients admitted to the hospital, commonly referred to as the hospital inpatient prospective payment system (IPPS). ASH explores how this will affect hematologists.

  • ASH Pleads for Payment Innovation in Rare Diseases Such As Sickle Cell Disease
    April 12, 2016

    As part of the American Society of Hematology’s (ASH) multifaceted initiative to address the burden of sickle cell disease, ASH is in the process of working with stakeholders to improve access to care for individuals with sickle cell disease.  Included in this effort is

  • Medicare Proposes Radical Experiment in Drug Payment Policy
    March 10, 2016

    On March 8, 2016, the Center for Medicare and Medicaid Services (CMS) proposed a new experiment in payment rates for physician-administered drugs such as chemotherapy. This plan would change the current formula for drug payment so that payments for expensive drugs are reduced in certain areas of the country. In a second phase, CMS would be able to adopt certain tools to further adjust pricing for drugs.

  • ASH Submits Comments to NHLBI on its Draft Strategic Research Priorities
    March 09, 2016

    ASH submitted comments to the National Heart, Lung and Blood Institute (NHLBI) on its recently released draft strategic research priorities that will inform the Institute’s policy and funding decisions for the next several years. ASH’s comments were developed based on the ASH Agenda for Hematology Research and input from members of the ASH Committee on Scientific Affairs and ASH Scientific Committees.

View all Policy News